Stephen J. Schuster

Goethe University Frankfurt — Germany

Medicine · Health Sciences

75h-index32.5kcitations803works6.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(407), CAR-T cell therapy research(341), Chronic Lymphocytic Leukemia Research(265), Viral-associated cancers and disorders(54), CNS Lymphoma Diagnosis and Treatment(44)

Publications802 total

Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma
Journal of Clinical Oncology·2025· 3 citedOpen Access
Cardiovascular outcomes of patients transitioned from ibrutinib to an alternate bruton tyrosine kinase inhibitor for hypertension and/or cardiovascular adverse events
Blood·2025
Precision targeting of pathogenic B cells and autoantibodies in systemic lupus erythematosus using CAR T cells against the IGHV4-34 B cell receptor
Blood·2025
Outcomes of patients with dual primary T-cell and B-cell lymphoid malignancies
Blood·2025Open Access
Outcomes in octo- and nonagenarians treated with mogamulizumab-based regimens for cutaneous T-cell lymphoma
Blood·2025
Frontline experience with second generation covalent Bruton tyrosine kinase inhibitors for mantle cell lymphoma: A single center experience
Blood·2025
Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies
Blood·2025
Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience
Blood·2025Open Access
Type II interferon-driven crosstalk between effector memory CART and myeloid cells is associated with CART19 resistance in relapsed refractory large B-cell lymphomas
Blood·2025Open Access
Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden
Blood·2025Open Access
Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study
Blood·2025Open Access
Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease
Blood·2025Open Access
Risk factors for failure to complete step-up-dosing of bispecific antibody therapy for B-cell lymphomas
Blood·2025Open Access
Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study
Blood·2025Open Access
Identification and functional characterization of a novel best-in-class anti-CD79b CAR T cell immunotherapy using a multidimensional screening strategy
Blood·2025
Supplementary table 6 from DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response
2025Open Access
A newly identified role for IL-5 in regulating CART-associated toxicity and efficacy
Blood·2025
Data from DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response
2025Open Access
Deep learning-based image analysis of pretreatment FDG-PET/CT predicts CAR-T cell treatment outcome at month-12 for patients with Relapsed/Refractory large B-cell lymphomas
Blood·2025Open Access
A retrospective multi-center review of the safety and efficacy of bispecific T-cell engagers in the management of post-transplant lymphoproliferative disorder – the bite PTLD study
Blood·2025Open Access
page 1 of 41Next →

Frequent Co-authors

Jakub Svoboda(14), Sunita D. Nasta(11), Carl H. June(10), Elise A. Chong(9), David L. Porter(9), Edward A. Stadtmauer(9), Daniel J. Landsburg(8), Simon F. Lacey(8), Anthony R. Mato(8), André Goy(7), Marco Ruella(7), Gilles Salles(6), Bruce L. Levine(6), Paul M. Barr(6), Nicole Lamanna(6), Donald E. Tsai(6), John P. Leonard(6), Constantine S. Tam(5), Charalambos Andreadis(5), Stephen M. Ansell(5)